Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT02654587 |
Title | Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1) |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | Yes |
Sponsors | OSE Immunotherapeutics |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | ITA | FRA | ESP | DEU |